Sialorphin TFA 是一种响应雄激素信号的中性内肽酶 (NEP) 和氨肽酶 N (APN) 抑制剂,能阻断内源性阿片肽降解并与 μ-、δ-、κ-阿片受体相互作用,通过诱导细胞周期阻滞、提高 ERK1/2 活性并降低 mTOR、4E-BP1、p70S6K 的磷酸化水平来调节 ERK/mTOR 信号通路,从而对结直肠癌、胶质瘤和前列腺癌细胞具有无细胞毒性的抗增殖活性,此外还具有抗伤害性感受反应、调节性行为、松弛阴茎海绵体平滑肌以及减轻实验性结肠炎的作用,同时也是一种铜 (II) 离子结合配体,已应用于癌症、疼痛管理及炎症性肠病等相关领域的机制研究中。
Sialorphin TFA
产品编号: MS-Q59181 分子式: C26H42N12O8·xC2Hf3O2 分子量: 650.69 (free base)
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
5mg
询价
3-5 天
10mg
询价
3-5 天
25mg
询价
3-5 天
50mg
询价
询价
100mg
询价
询价

产品描述

Sialorphin TFA 是一种响应雄激素信号的中性内肽酶 (NEP) 和氨肽酶 N (APN) 抑制剂,能阻断内源性阿片肽降解并与 μ-、δ-、κ-阿片受体相互作用,通过诱导细胞周期阻滞、提高 ERK1/2 活性并降低 mTOR、4E-BP1、p70S6K 的磷酸化水平来调节 ERK/mTOR 信号通路,从而对结直肠癌、胶质瘤和前列腺癌细胞具有无细胞毒性的抗增殖活性,此外还具有抗伤害性感受反应、调节性行为、松弛阴茎海绵体平滑肌以及减轻实验性结肠炎的作用,同时也是一种铜 (II) 离子结合配体,已应用于癌症、疼痛管理及炎症性肠病等相关领域的机制研究中。

生物实验数据

生物活性 Sialorphin TFA is an androgen-signaling-responsive inhibitor of neutral endopeptidase (NEP) and aminopeptidase N (APN) that blocks the degradation of endogenous opioid peptides and interacts with μ-, δ-, and κ-opioid receptors; by inducing cell cycle arrest, increasing ERK1/2 activity, and reducing the phosphorylation levels of mTOR, 4E-BP1, and p70S6K to modulate the ERK/mTOR signaling pathway, it exerts cytotoxic-free antiproliferative activity against colorectal cancer, glioma, and prostate cancer cells, and additionally exhibits antinociceptive responses, modulation of sexual behavior, relaxation of corpus cavernosum smooth muscle, and alleviation of experimental colitis, while also serving as a copper (II) ion-binding ligand, and has been applied in mechanistic studies in related fields such as cancer, pain management, and inflammatory bowel disease.
IC50 & Target

ERK1

 

ERK2

 

μ Opioid Receptor/MOR

 

κ Opioid Receptor/KOR

 

δ Opioid Receptor/DOR

 

体外研究
(In Vitro)

Sialorphin (10 μM;20 min) 可抑制大鼠脊髓切片中 Met -脑啡肽 (ME) 的分解,抑制率达 70%-96%,同时能抑制脊髓组织 (膜或切片) 中 3H-SP 的水解,抑制率为 55%,其抑制 3H-SP 分解的 IC50 为 3.9×10-7 M。
Sialorphin (400 nM-4000 nM;10-20 min) 对大鼠肾细胞膜中 3H-SP 的内肽酶水解具有浓度依赖性抑制作用,IC50 为 1 μM,且为竞争性抑制,与磷酰胺素抑制效果相当。

ELISA Assay

Cell Line: Rat spinal cord slice cells
Concentration: 4, 10 μM
Incubation Time: 20 min
Result: Effectively prevented the breakdown of exogenous ME by spinal enkephalinase ex vivo, with an inhibition rate ranging from 70% to 96%.
Inhibited the endoproteolysis of 3H-SP by rat renal membranes with a correlation coefficient (r) of 0.970.
At 4 μM, inhibited 60% of the specific SP - hydrolyzing activity of rat kidney tissue, which was as effective as phosphoramidon.
体内研究
(In Vivo)

Sialorphin TFA (0.3-10 mg/kg; i.p.; 每日 2 次; 3 d) 可显著减轻小鼠中 TNBS 诱导的急性结肠炎,减轻宏观损伤、溃疡、结肠壁增厚及降低 MPO 活性;该作用由 μ- 和 κ-阿片受体介导。
Sialorphin TFA (1 mg/kg; i.p.; 每日 2 次; 7 d) 可显著减轻小鼠中由 TNBS 诱导的慢性复发性结肠炎。
Sialorphin TFA (1 mg/kg; i.p.; 每日 2 次; 7 d) 在 40 KD DSS (MS-A45736) 诱导的小鼠结肠炎模型中未表现出抗炎活性。

Animal Model: BALB/c (male, 6-8 weeks old, 22-26 g, intracolonic instillation of TNBS to induce acute colitis)
Dosage: 0.3 mg/kg; 1 mg/kg; 3 mg/kg; 10 mg/kg
Administration: i.p.; twice daily; 3 days
Result: Significantly reduced macroscopic colonic damage scores, ulcer scores, colonic wall thickness, and myeloperoxidase (MPO) activity at 0.3, 1, and 3 mg/kg compared to TNBS-only controls.
Significantly reduced ulcer scores and colonic wall thickness, but did not reduce MPO activity, and only non-significantly reduced total macroscopic scores (p=0.09) at 10 mg/kg compared to TNBS-only controls.
Animal Model: BALB/c mice with Inflammatory bowel disease (male, 6-8 weeks old, 22-26 g, 4% wt/vol DSS in drinking water to induce colitis)
Dosage: 1 mg/kg
Administration: i.p.; twice daily; 7 days
Result: Significantly reduced macroscopic colonic damage scores, ulcer scores, colonic wall thickness, and MPO activity compared to TNBS-only controls.
Reduced body weight loss, decreased colon expression of pro-inflammatory cytokines TNFα and IL-1β, and lowered histological colon damage scores (reduced mucosal architecture destruction, smooth muscle thickening, crypt abscesses, and cellular infiltration) compared to TNBS-only controls.
Did not reduce any evaluated parameters of colitis, including macroscopic damage scores, colon weight, colon length, MPO activity, or body weight loss, compared to DSS-only controls.
性状 固体

化学信息

分子量 650.69 (free base)
分子式 C26H42N12O8·xC2Hf3O2

储存&溶解度

储存方式

Sealed storage, away from moisture

Powder -80°C 2 years
-20°C 1 year

*In solvent: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础